UroGen Pharma (URGN) stock falls as the company faces a major setback after an FDA panel votes against its bladder cancer ...

The FDA ODAC decided that the overall benefit-risk of the investigational therapy UGN-102 is not favorable in patients with ...

Anglo-Swedish pharma major AstraZeneca reports that it will have a historic presence at this year’s American Society of ...

Roger Li, MD, discusses the MoonRISe-1 study evaluating TAR-210 in FGFR-altered intermediate-risk non-muscle-invasive bladder cancer.

On Monday, Mad Money host Jim Cramer addressed the market’s reaction to the recent U.S. debt downgrade by Moody’s.

Celigo, the leading intelligent automation platform for business and IT users, today announced it has been recognized as a Visionary in the 2025 Gartner® Magic Quadranttm for iPaaS report for the ...

MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, and Kolosis BIO (Kolosis), a premier provider of ...

Dr. Hensley then polled the audience based on the following question: “Is there a role for artificial intelligence informed non muscle invasive bladder cancer risk stratification in 2025?”. The ...

The FDA's Oncologic Drugs Advisory Committee on Wednesday voted 5 to 4 against UroGen’s mitomycin as an option for low-grade ...

Virtuoso Surgical Inc., a Nashville-based surgical robotics company, today announced the first-in-human use of its Virtuoso system, ushering in a new era of precision and minimally invasive options ...

AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) ...

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.